Synthesis of peptide fragments spike glycoprotein SARS-CoV-2 and studying their binding with human blood cells

О. V. Gribovskaya; Грибовская О. В.; V. V. Yanchenko; Янченко В. В.; A. M. Tsygankov; Цыганков А. М.; V. P. Martinovich; Мартинович В. П.

doi:10.31857/S0132342324050062

Synthesis of peptide fragments spike glycoprotein SARS-CoV-2 and studying their binding with human blood cells

作者: Gribovskaya О.V.¹, Yanchenko V.V.², Tsygankov A.M.², Martinovich V.P.¹
隶属关系:
1. Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus
2. Vitebsk State medical University
期: 卷 50, 编号 5 (2024)
页面: 636-648
栏目: Articles
URL: https://rjmseer.com/0132-3423/article/view/670800
DOI: https://doi.org/10.31857/S0132342324050062
EDN: https://elibrary.ru/LRAMGQ
ID: 670800

如何引用文章

全文:

开放存取

##reader.subscriptionAccessGranted##
受限制的访问

订阅或者付费存取

详细

A new method was tested that allows to evaluate activation of the Spike surface protein of SARS-CoV-2 blood leukocytes by synthetic peptides, fragments Lys-Ile-Ala-Asp-Tyr-Asn-Tyr-Lys-Leu (417–425 аа) and Val-Arg-Gln-Ala-Pro-Asn-Gly-Gln-Thr (407–415 аа). It was found that these peptides, regardless of the HLA-A phenotype of the subjects, could bind to leukocytes, which indicates the universality of reactions to peptides, especially in innate immune cells. It was shown that the Lys-Ile-Ala-Asp-Tyr-Asn-Tyr-Lys-Leu peptide contacted the blood leukocytes of the subjects, activated the lymphocytes and basophils of the subjects (statistically significant), which was confirmed by an increase in gamma interferon compared to the Val-Arg-Gln-Ala-Pro-Asn-Gly-Gln-Thr. Thus, this work demonstrates an approach to creating a new peptide vaccine against COVID-19 at the stage of in vitro research.

关键词

SARS-CoV-2, peptide synthesis, gamma interferon, cellular immunity

全文:

参考

Mathieu E., Ritchie H., Ortiz-Ospina E., Roser M., Hasell J., Appel C., Giattino Ch., Rodés-Guirao L. // Nat. Hum. Behav. 2021. V. 5. P. 947–953. https://doi.org/10.1038/s41562-021-01122-8
Pollard A.J., Bijker E.M. // Nat. Rev. Immunology. 2021. V. 21. P. 83–100. https://doi.org/10.1038/s41577-020-00479-7
Park J.H., Lee H.K. // Vaccines. 2021. V. 9. P. 524–539. https://doi.org/10.3390/vaccines9050524
Yang H., Cao J., Lin X., Yue J., Zieneldien T., Kim J., Wang L., Fang J., Huang R.-P., Bai Yu., Sneed K., Cao Ch. // Viruses. 2022. V. 14. P. 449–463. https://doi.org/10.3390/v14030449
Heidary M., Kariar V.H., Shirani M., Ghanavati R., Motahar M., Sholeh M., Ghahramanpour H., Khoshnood S. // Front. Microbiol. 2022. V. 13. P. 927306–927306. https://doi.org/10.3389/fmicb.2022.927306
Chiplunkar S., Baravkar A., Paricharak S., Masal A., Aher N. // J. Young. Pharm. 2022. V. 14. P. 133–139.
Triccas J.A., Kint J., Wurm F.M. // NPJ Vaccines. 2022. V. 7. P. 1–2. https://doi.org/10.1038/s41541-022-00507-8
Hanan N., Doud R.L., Jr., Park In-W., Jones H.P., Mathew S.O. // Vaccines. 2021. V. 9. P. 596–613. https://doi.org/10.3390/vaccines9060596
Крит Н.А., Филатова Н.П., Ковальчук О.В., Бесчастная Н.В. // Биоорг. химия. 1981. Т. 7. С. 965–970.
Hermiston M.L., Xu Z., Weiss A. // Annu. Rev. Immunol. 2003. V. 21. P. 107–137. https://doi.org/10.1146/annurev.immunol.21.120601.140946
Sancho D., Gomez M., Sanchez-Madrid F. // Trends Immunol. 2005. V. 26. P. 136–140. https://doi.org/10.1016/j.it.2004.12.006
Gorelik A., Randriamihaja A., Illes K., Nagar B. // FEBS J. 2018. V. 285. P. 2481–2494. https://doi.org/10.1111/febs.14489
Pols M.S., Klumperman J. // Exp. Cell Res. 2009. V. 315. P. 1584–1592. https://doi.org/10.1016/j.yexcr.2008.09.020
Murugesan K., Jagannathan P., Pham Th.D., Pandey S., Bonilla H.F., Jacobson K., Parsonnet J., Andrews J.R., Weiskopf D., Sette A., Pinsky B.A., Singh U., Banaei N. // Clin. Infect. Dis. 2021. V. 73. P. 3130–3132. https://doi.org/doi: 10.1093/cid/ciaa1537
Aiello A., Coppola A., Vanini V., Petrone L., Cuzzi G., Salmi A., Altera A.M.G., Tortorella C., Gualano G., Gasperini C., Scolieri P., Beccacece A., Vita S., Bruzzese V., Lorenzetti R., Palmieri F., Nicastri E., Goletti D. // Int. J. Infect. Dis. 2022. V. 122. P. 841– 849. https://doi.org/10.1016/j.ijid.2022.07.049
Todorovic-Rakovic N., Whitfield J.R. // Cytokine. 2021. V. 146. P. 1537–1556. https://doi.org/10.1016/j.cyto.2021.155637